The Resolution ctDx Lung assay is a NGS multi-gene panel that assesses circulating tumor DNA (CtDNA) from a plasma sample in patients with non-small cell lung cancer. It is intended to identify key driver mutations and variants to enable treatment decisions for patients. With targeted therapies available for many of the driver mutations in NSCLC, its critical to determine which mutation is driving the cancer. Some of these therapies are second generation and overcome known resistance mutations to earlier therapies, such as EGFR T790M or ALK L1196M or ALK G1269A. The liquid biopsy allows for serial, near real-time assessment of the tumor genotype as the tumor evolves under therapy.
Non Small Cell Lung Cancer
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), HER-2 (Human epidermal growth factor receptor 2)
See More ...
Alecensa (alectinib), Alunbrig (brigatinib), Gilotrif (afatinib), Lorbrena (lorlatinib), Mekinist (trametinib), Rozlytrek (entrectinib), Tafinlar (dabrafenib), Tagrisso (osimertinib), Vitrakvi (larotrectinib), Vizimpro (dacomitinib), Xalkori (crizotinib), Zykadia (ceritinib), erlotinib, gefitinib
Circulating tumor DNA (ctDNA)